Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

31.20 -0.88 (-2.73%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Gains 1%; Macy's Plans To Close 150 Stores
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Janux Therapeutics Nearly Triples As Prostate Cancer Drug Shows 'Significant Opportunity'
The company is working on a treatment for metastatic castration-resistant prostate cancer. 
Via Investor's Business Daily
Why Is Infobird (IFBD) Stock Up Today?
Infobird stock is up on Tuesday after the SaaS company announced a delay to a planned reverse stock split for shares of IFBD. 
Via InvestorPlace
Janux Therapeutics: Q1 Earnings Insights
Via Benzinga
Nasdaq Rises 50 Points; Lowe's Earnings Top Views
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Aaron’s (AAN) Stock Down 22% Today?
Aaron’s stock is taking a beating on Tuesday as AAN investors react to the company's lackluster earnings report for Q4 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. 
Via Benzinga
Why Is Janux Therapeutics (JANX) Stock Up 108% Today?
Janux Therapeutics stock is rocketing higher on Tuesday after the company provided JANX shareholders with clinical trial updates. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news affecting shares on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
From Janux Therapeutics
Via Business Wire
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
From Janux Therapeutics
Via Business Wire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
Via Benzinga
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Exposures US Equities
$27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Becton, Dickinson and Company, Applied Digital, POSCO And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential
Janux Therapeutics Inc (NASDAQ: JANX) announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration- 
Via Benzinga
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.